Market Overview

UPDATE: Morgan Stanley Upgrades Teva Pharmaceutical Industries on Copaxone 3TW Success

Share:
Related TEVA
Benzinga's M&A Chatter for Wednesday May 27, 2015
Report: Mylan Could See Sweetened Bid From Teva Pharmaceutical
Teva Settles Provigil Drug Delay Charge with FTC for $1.2B - Analyst Blog (Zacks)

In a report published Friday, Morgan Stanley analyst David Risinger upgraded the rating on Teva Pharmaceutical Industries (NYSE: TEVA) from Underweight to Equal-Weight, and named a $52.00 price target.

In the report, Morgan Stanley noted, “Launch of the new 3TW (3 times per week) formulation of Copaxone succeeds in partially diminishing the threat from once daily generics in May '14. Physicians and patients appear to be embracing the new 3TW formulation, and conversion to date has exceeded our expectations. We now expect Teva to reach its conversion goals (35% by June 1 and 57% by the end of the year). New CEO Eroz Vigodman is a proven turnaround expert, and we expect him to pursue new external growth opportunities.”

Teva Pharmaceutical Industries closed on Thursday at $47.93.

Latest Ratings for TEVA

DateFirmActionFromTo
Apr 2015Standpoint ResearchUpgradesHoldBuy
Apr 2015Argus ResearchMaintainsBuy
Apr 2015BMO CapitalDowngradesOutperformMarket Perform

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: David Risinger Morgan StanleyAnalyst Color Upgrades Analyst Ratings

 

Related Articles (TEVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters